Literature DB >> 28069404

Calculated panel reactive antibody with decimals: A refined metric of access to transplantation for highly sensitized candidates.

Evan P Kransdorf1, Marcelo J Pando2.   

Abstract

The use of the calculated panel reactive antibody (CPRA) value and the implementation of allocation points for sensitized candidates by the United Network for Organ Sharing (UNOS) have improved access to kidney transplantation for highly sensitized candidates (98% CPRA and above). Despite this, a large population of highly sensitized candidates remain awaiting transplantation. To better define this population, we propose the use of two refinements of the standard UNOS CPRA, the CPRA with decimals or CPRAd, and the likelihood of a compatible donor (LCD). These refined metrics of the standard UNOS CPRA will allow transplant programs to describe their patients' access to transplantation with increased granularity and will help in decisions regarding the use of desensitization.
Copyright © 2017 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Calculated panel reactive antibody; Histocompatibility; Sensitization; Transplantation

Mesh:

Substances:

Year:  2017        PMID: 28069404     DOI: 10.1016/j.humimm.2016.12.009

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  2 in total

1.  Alloimmune Risk Stratification for Kidney Transplant Rejection.

Authors:  Oriol Bestard; Olivier Thaunat; Maria Irene Bellini; Georg A Böhmig; Klemens Budde; Frans Claas; Lionel Couzi; Lucrezia Furian; Uwe Heemann; Nizam Mamode; Rainer Oberbauer; Liset Pengel; Stefan Schneeberger; Maarten Naesens
Journal:  Transpl Int       Date:  2022-05-20       Impact factor: 3.842

2.  European Guideline for the Management of Kidney Transplant Patients With HLA Antibodies: By the European Society for Organ Transplantation Working Group.

Authors:  Nizam Mamode; Oriol Bestard; Frans Claas; Lucrezia Furian; Siân Griffin; Christophe Legendre; Liset Pengel; Maarten Naesens
Journal:  Transpl Int       Date:  2022-08-10       Impact factor: 3.842

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.